Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

Am J Hematol. 2019 Aug;94(8):E216-E219. doi: 10.1002/ajh.25515. Epub 2019 Jun 7.

Authors

Affiliations

¹ Department of Medicine, Department of Hematology and Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.
² Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland.

PMID: 31120638
DOI: 10.1002/ajh.25515

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ABO Blood-Group System
Allografts
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Erythrocyte Transfusion / adverse effects
Erythrocyte Transfusion / methods
Hematopoietic Stem Cell Transplantation / adverse effects*
Hematopoietic Stem Cell Transplantation / methods
Humans
Male
Middle Aged
Myelodysplastic Syndromes / blood
Myelodysplastic Syndromes / therapy*
Red-Cell Aplasia, Pure / blood
Red-Cell Aplasia, Pure / drug therapy*
Red-Cell Aplasia, Pure / etiology
Treatment Outcome

Substances

ABO Blood-Group System
Antibodies, Monoclonal
Antineoplastic Agents
daratumumab